-
Sulforaphane Limits PM2.5-Driven COPD Injury
2026-09-28
A 2026 study reports that sulforaphane attenuates PM2.5-associated lung injury in experimental COPD models, linking antioxidant Nrf2 activity with suppression of EGFR/PI3K/AKT signaling. Its combination of animal and cell experiments, network pharmacology, molecular docking, and EGFR silencing offers a mechanistic framework, although the available report does not establish clinical efficacy or provide enough protocol detail to reproduce exposure conditions.
-
MLKL Polymers Trigger Lysosomal Permeabilization
2026-09-26
The study identifies MLKL polymerization-induced lysosomal membrane permeabilization as an execution step in necroptosis, occurring before plasma membrane rupture. Imaging and cathepsin B perturbation experiments connect lysosomal damage to cytosolic protease release and cell death, refining the mechanism by which activated MLKL drives necroptosis.
-
Deferiprone: Iron-Chelation Workflows for Research
2026-09-26
Deferiprone offers a practical way to test whether iron availability contributes to oxidative injury, apoptosis, or altered cell behavior. This guide connects a recent sickle cell kidney-injury study to adaptable cell and animal workflows, with clear handling and troubleshooting guidance.
-
Esculetin Limits CKLF1-Linked Inflammation After Stroke
2026-09-25
A mouse study links esculetin’s post-stroke benefits to reduced CKLF1–CCR5 signaling and neutrophil recruitment, combining behavioral, imaging, tissue, and cell-based evidence. The findings support CKLF1-mediated inflammation as a candidate mechanism for recovery research, while leaving clinical efficacy and direct molecular targeting unresolved.
-
Cisplatin (CDDP): Mechanisms and Research Use
2026-09-25
Cisplatin (CDDP) is a DNA-crosslinking chemotherapeutic used in cancer research to study DNA damage, apoptosis, and tumor response. A 2023 study also reports that pharmacological SMYD2 inhibition reduced cisplatin-associated renal injury and fibrosis in experimental models, an important boundary when interpreting its biological effects.
-
SmD2 Acetylation Shapes HCC Splicing and PARP Response
2026-09-24
This study identifies SmD2, a core spliceosome protein, as an acetylation-regulated factor that connects cassette-exon choice with DNA repair and PARP inhibitor sensitivity in hepatocellular carcinoma. Its findings support a testable combination strategy involving HDAC inhibition and PARP inhibition, while highlighting the need to validate the mechanism and treatment response across HCC models.
-
From Podocyte Injury to Translational Renal Models
2026-09-24
Puromycin aminonucleoside is more than a nephrotoxic challenge: it is a tool for connecting podocyte structure, filtration failure, and disease-relevant readouts. This article outlines how to use the model strategically, interpret its limits, and build a more translational evidence chain.
-
HyperFluor 488 Goat Anti-Mouse IgG for ATII Assays
2026-09-23
Build sensitive ATII-cell assays around a fluorescently labeled secondary antibody that connects mitochondrial imaging with flow cytometry and immunoblot validation. This workflow translates hyperoxia-induced DRP1 and glycolytic changes into practical staining, signal-control, and troubleshooting decisions.
-
MLN8237 and Aurora A: From Mitosis to Immunity
2026-09-23
MLN8237 (Alisertib) offers a precise way to interrogate Aurora A biology across mitosis, apoptosis, tumor growth, and trained immunity. Integrating product pharmacology with Li et al.’s 2025 findings on SAM metabolism, this article presents a translational framework for connecting kinase inhibition to chromatin state, inflammatory memory, and cancer response—while clearly separating established evidence from testable hypotheses.
-
Chrysin Sensitizes RCC to Sunitinib via Ferroptosis
2026-09-22
A 2025 study found that chrysin increases sunitinib sensitivity in renal cell carcinoma (RCC) by suppressing PI3K/Akt signaling and reducing SLC7A11 and GPX4, thereby promoting ferroptosis. Its combination of computational target analysis, cell-based phenotyping, ferroptosis measurements, and pathway-rescue experiments provides a mechanistic framework for studying resistance-directed combination therapy.
-
Camptothecin Workflow for DNA Damage Studies
2026-09-21
Camptothecin combines a defined topoisomerase I mechanism with measurable DNA damage, senescence, apoptosis, and autophagy responses. This workflow shows how to turn that pharmacology into reproducible cell-based assays while using evolutionary insights from prion research to improve experimental design.
-
Ethacridine Lactate Monohydrate in Stem Cell Assays
2026-09-21
Ethacridine lactate monohydrate can support microbial growth inhibition in demanding biochemical and cellular workflows. This article connects its formulation and handling requirements with the YAP–TEAD super-enhancer study, showing how antiseptic control can be integrated without confusing contamination management with lineage-regulatory biology.
-
Cisplatin A8321: Reliable Cytotoxicity Assays
2026-09-20
This scenario-driven guide shows how Cisplatin (SKU A8321) can help researchers control solubility, exposure timing, apoptosis readouts, and chemoresistance experiments. It connects practical assay decisions with DNA-crosslinking biology and recent colorectal cancer evidence.
-
Cinoxacin: In Vitro Activity and Resistance Findings
2026-09-19
The 1975 reference study established a quantitative in vitro profile for Cinoxacin across 419 clinical isolates, emphasizing activity against gram-negative aerobic bacteria, disk diffusion correlation, bactericidal behavior, and readily selected resistance. Its agar-dilution and serial-passage design remains useful for urinary tract infection research and antibiotic resistance studies, while its historical methods require careful interpretation in modern workflows.
-
IWP-2: From Wnt Secretion to Cell-State Assays
2026-09-19
IWP-2 is a potent Wnt production inhibitor for dissecting Porcupine-dependent signaling and downstream cell phenotypes. This article connects mechanistic pathway control with cell-resolved assay design, using gastric cancer evidence and single-nucleus research as a framework for more rigorous interpretation.